Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ra Capital Management, Llc Insider Profile
18 Followers
Ra Capital Management, Llc, Former 10% Owner. See FN(1)(6) at Achillion Pharmaceuticals, holds 14.18M shares in 89bio (Ticker: ETNB), holds 8.34M shares in Acrivon Therapeutics, Inc. (Ticker: ACRV), holds 295.84K shares in Boundless Bio Inc. (Ticker: BOLD). Most recently, Ra Capital Management, Llc Bought ― shares of 89bio on Apr 15, 2024 for an estimated value of 7.49M.
Ra Capital Management, Llc Achillion Pharmaceuticals (~ACHN)Former 10% Owner. See FN(1)(6)
Achillion Pharmaceuticals (~ACHN)
Former 10% Owner. See FN(1)(6)
Ranked #24,506 out of 98,501 Corporate Insiders
Profitable Transactions
36 out of 122 Profitable Transactions
Average Return
+1.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Ra Capital Management, Llc's holdings
Insider Roles
Roles that Ra Capital Management, Llc holds in companies
Most Profitable Insider Trade
The most profitable trade made by Ra Capital Management, Llc
Ra Capital Management, Llc's Trading History
Achillion Pharmaceuticals
Jan 20, 2015
―
Informative Sell
1.44M
$32.56M
Aclaris Therapeutics
Sep 19, 2016
Ten Percent Owner
Informative Sell
12.71M
$2.54M
KalVista Pharmaceuticals
Oct 16, 2017
Director
Informative Buy
7.22M
$6.94M
Wave Life Sciences
Dec 13, 2023
Director, Ten Percent Owner
Informative Buy
5.00M
$110.22M
Ra Pharmaceuticals
Apr 03, 2020
―
Uninformative Sell
233.20M
$0.00
Eidos Therapeutics
Jun 22, 2018
―
Uninformative Buy
―
$264.30M
Arvinas Holding Company
Oct 03, 2018
Former 10% Owner
Informative Buy
16.00M
$108.97M
Kala Pharmaceuticals
May 26, 2022
Ten Percent Owner
Informative Sell
362.05K
$49.28M
Thoratec Corp
Dec 13, 2018
―
Uninformative Buy
―
$617.51M
scPharmaceuticals
Mar 16, 2021
Ten Percent Owner
Informative Sell
1.06M
$13.26M
Satsuma Pharmaceuticals
Jun 12, 2023
―
Uninformative Sell
―
$0.00
89bio
Apr 15, 2024
Director, Ten Percent Owner
Informative Buy
7.49M
$134.52M
Synthorx
Jan 24, 2020
―
Uninformative Sell
661.27M
$0.00
Enliven Therapeutics
Feb 27, 2023
Former 10% owner
Uninformative Buy
―
$42.32M
Phathom Pharmaceuticals
Mar 15, 2021
Ten Percent Owner
Informative Sell
31.06M
$31.21M
Verastem
Jun 29, 2020
Ten Percent Owner
Informative Sell
2.22M
$178.69M
Forma Therapeutics Holdings
Oct 14, 2022
―
Uninformative Sell
―
$0.00
Rhythm Pharmaceuticals
Dec 04, 2020
Former 10% Owner
Informative Sell
7.03M
$174.83M
AKOUOS
Jul 02, 2020
―
Uninformative Buy
―
$30.32M
Nkarta
Mar 29, 2024
Director, Ten Percent Owner
Informative Buy
30.00M
$94.33M
Pandion Therapeutics
Jul 22, 2020
―
Uninformative Buy
―
$106.29M
Inozyme Pharma
Jul 28, 2020
Ten Percent Owner
Uninformative Buy
―
$9.44M
iTeos Therapeutics
Apr 05, 2021
Director, Ten Percent Owner
Uninformative Buy
14.40M
$48.54M
Inhibrx
Aug 24, 2020
Ten Percent Owner
Uninformative Buy
―
$73.96M
TG Therapeutics
Sep 11, 2020
Ten Percent Owner
Informative Sell
4.09M
$177.70M
Dyne Therapeutics
Sep 23, 2020
Ten Percent Owner
Uninformative Buy
―
$71.36M
PMV Pharmaceuticals
Sep 29, 2020
Ten Percent Owner
Uninformative Buy
―
$2.80M
Vaxcyte
Oct 01, 2020
Ten Percent Owner
Informative Sell
11.24M
$329.66M
Orchard Therapeutics
Nov 06, 2020
―
Informative Buy
3.56M
$165.01M
Iterum Therapeutics
Feb 08, 2021
Ten Percent Owner
Uninformative Buy
―
$18.29M
Vor Biopharma
Dec 09, 2022
Director, Ten Percent Owner
Uninformative Buy
50.00M
$40.95M
Solid Biosciences
Jan 12, 2024
Director, Ten Percent Owner
Informative Buy
5.00M
$43.02M
Werewolf Therapeutics
Jan 10, 2023
Director, Ten Percent Owner
Informative Buy
4.10M
$33.74M
Janux Therapeutics Inc
Jul 21, 2023
Director, Ten Percent Owner
Informative Buy
6.17M
$475.33M
Aerovate Therapeutics
Jul 06, 2021
Director, Ten Percent Owner
Uninformative Buy
―
$7.87M
Acumen Pharmaceuticals
Jul 25, 2023
Director, Ten Percent Owner
Informative Buy
40.00M
$52.71M
POINT Biopharma Global
Jun 30, 2021
―
Informative Buy
2.09M
$13.73M
Cytek Biosciences
Mar 16, 2022
Director, Ten Percent Owner
Uninformative Buy
7.19M
$80.55M
Icosavax
Feb 20, 2024
―
Uninformative Sell
―
$0.00
Eliem Therapeutics
Aug 16, 2021
Director, Ten Percent Owner
Uninformative Buy
―
$4.00M
Tyra Bioscience
Feb 08, 2024
Director, Ten Percent Owner
Uninformative Buy
41.37M
$153.64M
Dice Therapeutics
Aug 09, 2023
―
Uninformative Sell
―
$0.00
AN2 Therapeutics, Inc.
Aug 22, 2023
Ten Percent Owner
Informative Buy
16.00M
$13.88M
PepGen Inc.
Feb 13, 2024
Director, Ten Percent Owner
Informative Buy
27.21M
$130.73M
ARS Pharmaceuticals
Mar 27, 2024
Director, Ten Percent Owner
Informative Buy
13.29M
$100.36M
Fulcrum Therapeutics
Jan 24, 2023
Ten Percent Owner
Informative Buy
25.00M
$85.45M
Mineralys Therapeutics, Inc.
Feb 14, 2024
Director
Uninformative Buy
22.58M
$59.86M
Black Diamond Therapeutics
Jul 07, 2023
Director
Informative Buy
4.68M
$18.40M
LENZ Therapeutics
Mar 25, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$28.40M
Boundless Bio Inc.
Apr 04, 2024
Ten Percent Owner
Uninformative Buy
―
$3.19M
Acrivon Therapeutics, Inc.
Apr 15, 2024
Director, Ten Percent Owner
Uninformative Buy
30.00M
$80.15M
Sangamo Biosciences
Feb 18, 2015
Former 10% Owner
Informative Sell
1.33M
$3.06M
Biospecifics Technologies
Feb 26, 2010
―
Informative Sell
288.30K
$55.46M
Dicerna Pharma
Dec 20, 2017
―
Uninformative Buy
―
$193.93M
Sequenom
―
―
―
$27.21M
Curis
―
Ten Percent Owner
―
$91.01M
Derma Sciences
Jan 13, 2014
―
Informative Sell
3.55M
$11.86M
Aradigm
―
―
―
$49.74K
List of latest transactions for each holding click on a transaction to see Ra Capital Management, Llc's performance on stock
You May Also Like
Ra Capital Management, Llc insider profile FAQ
What is the percentage of profitable transactions made by Ra Capital Management, Llc?
The percentage of profitable transactions made by Ra Capital Management, Llc is 30%.
What is the average return per transaction made by Ra Capital Management, Llc?
The average return per transaction made by Ra Capital Management, Llc is 1.20%.
What stocks does Ra Capital Management, Llc hold?
Ra Capital Management, Llc holds: ~ACHN, ACRS, KALV, WVE, RARX, EIDX, ARVN, KALA, ~THOR, SCPH, STSA, ETNB, THOR, ELVN, PHAT, VSTM, FMTX, RYTM, AKUS, NKTX, PAND, INZY, ITOS, INBX, TGTX, DYN, PMVP, PCVX, ORTX, ITRM, VOR, SLDB, HOWL, JANX, AVTE, ABOS, PNT, CTKB, ICVX, ELYM, TYRA, DICE, ANTX, PEPG, SPRY, FULC, MLYS, BDTX, LENZ, BOLD, ACRV, SGMO, BSTC, DRNA, SQNM, CRIS, DSCI, ARDMQ stocks.
What was Ra Capital Management, Llc’s latest transaction?
Ra Capital Management, Llc latest transaction was an Informative Buy of $7.49M.
What was Ra Capital Management, Llc's most profitable transaction?
Ra Capital Management, Llc’s most profitable transaction was an Informative Buy of ETNB stock on July 6, 2022. The return on the trade was 497.40%.
What is Ra Capital Management, Llc's role in Achillion Pharmaceuticals?
Ra Capital Management, Llc's role in Achillion Pharmaceuticals is Former 10% Owner. See FN(1)(6).
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.